JBJ-09-063 chemical structure, allosteric mutant-EGFR inhibitor - Dana-Farber Cancer Institute, Boston, MA

allosteric mutant-EGFR inhibitor

in vivo efficacy in osimertinib-resistant xenograft models

from opt. of prev. disclosed EGFR inhibitor

Nat. Cancer

Dana-Farber Cancer Institute, Boston, MA

Context. JBJ-09-063 (Dana-Farber Cancer Institute) is an oral allosteric EGFR inhibitor currently in pre-clinical development for the treatment of EGFR L858R-mutant non-small cell lung cancer (NSCLC). Despite the availability…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.